Aratana was granted the award based on the FDA approval of three innovative therapeutics in 2016, GALLIPRANT® (grapiprant tablets), ENTYCE® (capromorelin oral solution) and NOCITA® (bupivacaine liposome injectable suspension), as well as the Company’s evolution to a fully integrated commercial company. This is the third consecutive year Aratana has been honored with an award from Animal Pharm.